|
Volumn 18, Issue 10, 2016, Pages 1073-
|
Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?
a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CALCIUM CHANNEL BLOCKING AGENT;
CANAGLIFLOZIN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
ANTIDIABETIC AGENT;
GLUCOSIDE;
GLYCOSYLATED HEMOGLOBIN;
SODIUM GLUCOSE COTRANSPORTER 2;
AFRICAN AMERICAN;
ANTIHYPERTENSIVE ACTIVITY;
BLOOD PRESSURE MONITORING;
BLOOD PRESSURE REGULATION;
BODY MASS;
COMORBIDITY;
DIASTOLIC BLOOD PRESSURE;
DIURESIS;
DRUG EFFICACY;
ETHNIC DIFFERENCE;
HISPANIC;
HUMAN;
HYPERTENSION;
HYPOVOLEMIA;
INDIVIDUALIZATION;
KIDNEY DYSFUNCTION;
LETTER;
MEDICAL DECISION MAKING;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
ORTHOSTATIC HYPOTENSION;
PRIORITY JOURNAL;
SYSTOLIC BLOOD PRESSURE;
TREATMENT OUTCOME;
DOUBLE BLIND PROCEDURE;
GLUCOSE BLOOD LEVEL;
BLOOD GLUCOSE;
CANAGLIFLOZIN;
DIABETES MELLITUS, TYPE 2;
DOUBLE-BLIND METHOD;
GLUCOSIDES;
GLYCATED HEMOGLOBIN A;
HUMANS;
HYPERTENSION;
HYPOGLYCEMIC AGENTS;
SODIUM-GLUCOSE TRANSPORTER 2;
|
EID: 84963956773
PISSN: 15246175
EISSN: 17517176
Source Type: Journal
DOI: 10.1111/jch.12832 Document Type: Letter |
Times cited : (5)
|
References (5)
|